Sandoz Asks For Distinct Reimbursement Code For First U.S. Biosimilar

Sandoz lobbied a CMS Healthcare Common Procedure Coding System (HCPCS) panel Thursday (May 7) to give the company's recently approved filgrastim biosimilar Zarxio a separate and unique reimbursement code for Medicare Part B. The company argued that all biosimilars, even ones that share a reference product, should have unique reimbursement code to avoid confusion among providers and dispensers and to help create a viable market for biosimilars in the United States. The HCPCS panel has assigned Zarxio a preliminary code...